Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bucillamine in cystinuria
NCT02942420Phase 2Unknown
- Sponsor
- Revive Therapeutics
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bucillamine in cystinuria (CSNU) (2 arms), sponsored by Revive Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Status: unknown.
02
Drugs
bucillamine
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on NCT02942420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942420.